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Abstract
Recent studies have suggested that schizophrenia is associated with alterations in the synaptic connectivity involving cytoskeletal
proteins. The microtubule-associated protein STOP (Stable Tubule Only Polypeptide) plays a key-role in neuronal architecture and
synaptic plasticity and it has been demonstrated that STOP gene deletion in mice leads to a phenotype mimicking aspects of positive
and negative symptoms and cognitive deficits classically observed in schizophrenic patients. In STOP-null mice, behavioral defects
are associated with synaptic plasticity abnormalities including defects in long-term potentiation. In these mice, long-term
administration of typical antipsychotics has been shown to partially alleviate behavioral defects but, as in humans, such a treatment
was poorly active on deficits related to negative symptoms and cognitive impairments. Here, we assessed the effects of risperidone and
clozapine, two atypical antipsychotics, on STOP-null mice behavior and synaptic plasticity. Long-term administration of either drug
results in alleviation of behavioral alterations mimicking some negative symptoms and partial amelioration of some cognitive defects
in STOP-null mice. Interestingly, clozapine treatment also improves synaptic plasticity of the STOP- null animals by restoring
long-term potentiation in the hippocampus. All together, the pharmacological reactivity of STOP-null mice to antipsychotics evokes
the pharmacological response of humans to such drugs. Totally, our study suggests that STOP-null mice may provide a useful
preclinical model to evaluate pharmacological properties of antipsychotic drugs.
MESH Keywords Animals ; Antipsychotic Agents ; pharmacology ; Behavior, Animal ; drug effects ; Clozapine ; pharmacology ; Drug Evaluation, Preclinical ; methods ; 
Hippocampus ; drug effects ; metabolism ; Male ; Mice ; Mice, Knockout ; Microtubule-Associated Proteins ; genetics ; Neuronal Plasticity ; drug effects ; Risperidone ; 
pharmacology
Author Keywords schizophrenia, STOP-null mice, cognitive defects, social investigation, antipsychotics
Introduction
Schizophrenia is a chronic disease characterized by positive, negative or mood symptoms and cognitive deficits. Common negative
symptoms include lack of motivation, anhedonia and social withdrawal. Cognitive dysfunctions encompass affected attention and
perception, problem-solving, short- and long-term memory. Schizophrenia symptoms are sensitive to antipsychotics (APs) which can be
classified as follows: typical APs known to be mainly efficient in improving positive symptoms ( ; Ereshefsky et al. 1990 Mueser and
), atypical AP drugs (e.g., risperidone and clozapine) known to partially act on negative symptoms and cognitive function (McGurk 2004 
). Atypical agents have been found to increase cortical dopamine and acetylcholine release, and have some effects on theMeltzer 2004 
glutamatergic system not shared by the typical agents ( ). Effects on neuronal survival and plasticity, together withCoyle and Tsai 2004 
decreased neurotoxicity, might also contribute to their clinical advantage over typical AP drugs ( ).Meltzer 2004 
However, there is consensus that none of the currently available APs completely alleviate the core symptoms and the debilitating
cognitive dysfunction associated with schizophrenia ( ; ). Monitoring reactivity of the symptoms toPeuskens et al. 2005 Sergi et al. 2007 
AP treatment in a preclinical model exhibiting positive, negative and cognitive disorders may help developing drugs that better target each
kind of symptoms and could ultimately lead to better outcome and quality of life for patients.
At the physiopathological level, several lines of evidence suggest that schizophrenia is associated with alterations of neuronal
architecture, particularly in the synaptic connectivity ( ; ; ; ).Frankle et al. 2003 Mirnics et al. 2001 Owen et al. 2005a Owen et al. 2005b 
Recently, the protein disrupted-in-schizophrenia1 (DISC1) has been demonstrated to bind to microtubules; its truncation in schizophrenic
patients contributes to impair intraneuronal transport, neurite cytoarchitecture, and/or neuronal migration ( ; Duan et al. 2007 Mackie et al.
; ; ; ). Dysbindin, another protein linked to schizophrenia is also2007 Matsuzaki and Tohyama 2007 Shinoda et al. 2007 Taya et al. 2007 
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able to bind and regulate microtubules ( ). Thus, cytoskeletal alterations in general and more specifically abnormalTalbot et al. 2006 
microtubule dynamics may contribute to connectivity disorders observed in schizophrenia ( ; ; Blackwood et al. 2007 Camargo et al. 2008 
; ; ; ).Chiba et al. 2006 Clapcote et al. 2007 Hikida et al. 2007 Ishizuka et al. 2006 
Consistent with this hypothesis, disruption of the MAP6 gene ( ) encoding a microtubule-associated protein calledDenarier et al. 1998 
STOP (Stable Tubule Only Polypeptide) in mice generated a set of defects similar to those of schizophrenia disorders (Andrieux et al.
). Correlatively, the MAP6 gene - the human homologous of STOP gene - is localized on chromosome 11q14, a region highly2002 
associated with schizoid personality disorders ( ). Interestingly, an association between single nucleotide polymorphismLewis et al. 2003 
markers of the MAP6 gene and schizophrenia has been found, together with a dysregulation of the isoform2 of MAP6 transcripts in the
frontal cortex of schizophrenic patients ( ).Shimizu et al. 2006 
The STOP-null mice, at the behavioral level, have been shown to display behavioral abnormalities thought to simulate some aspects of
positive symptoms classically observed in schizophrenic patients ( ; ). These mice exhibit increasedAndrieux et al. 2002 Brun et al. 2005 
basal locomotor activity during the dark phase of the light/dark cycle associated with purposeless and disorganized activity (Andrieux et
; ). Additionally, STOP-null mice display a hyper-sensitive locomotor reaction to acutely stressful situations,al. 2002 Brun et al. 2005 
such as a single saline injection or exposure to novelty and an increased locomotor stimulatory effect of psychotomimetic drugs such as
amphetamine ( ). Some of these locomotor activity defects are present in juvenile mice, whereas others appear only inBrun et al. 2005 
adulthood mimicking thus the life-long evolution of the pathology ( ). Regarding negative or cognitive abilities,Begou et al. 2007 
STOP-null mice exhibit strong defects such as social withdrawal with dramatically reduced aggressive encounters ( ),Andrieux et al. 2002 
deficits in prepulse inhibition ( ; ; ; ) and recognitionAndrieux et al. 2002 Bouvrais-Veret et al. 2007 Fradley et al. 2005 Powell et al. 2007 
memory ( ), spatial and social learning impairments ( ). STOP-null mice also exhibit hyper-reactivityPowell et al. 2007 B gou et al. 2008 é
of dopamine release ( ) associated with an hypoglutamatergic phenotype ( ; ), inBrun et al. 2005 Andrieux et al. 2002 Brenner et al. 2007 
accordance with the dopamine/glutamate neurotransmission imbalance hypothesis in schizophrenia. Hence, STOP-null mice exhibit both
short and long term synaptic plasticity defects in the hippocampus ( ) associated with depleted glutamatergic vesicleAndrieux et al. 2002 
pools. Moreover, levels of mRNAs encoding synaptic proteins, such as synaptophysin, growth-associated protein-43 and spinophilin are
decreased in specific hippocampic sub-regions ( ).Eastwood et al. 2007 
Consistently with clinical data, long-term treatment with typical APs, such as haloperidol, has been shown to suppress
hyperlocomotion disorders in STOP-null mice ( ) as well as poorly effective on negative and cognitive defects (Brun et al. 2005 B gou eté
). At the biological level, typical AP treatment has been shown to reverse short term plasticity defects and to be ineffective onal. 2008 
long term plasticity ( ). Here, we tested the effect of atypical APs, namely clozapine and risperidone, administratedAndrieux et al. 2002 
chronically, on several impaired behaviors exhibited by STOP-null mice. We found that atypical AP administration in STOP-null mice
resulted in noticeable amelioration of the negative symptoms and in a partial alleviation of the cognitive defects. Correlatively, we showed
that clozapine treatment was able to restore hippocampal long term synaptic plasticity in STOP-null mice.
Materials and methods
Animals
Male STOP-null mice (STOP / ) and their wild-type (WT) littermates (STOP / ) were generated as previously described (− − + + Andrieux
). Eight mice were housed per cage in a temperature-controlled environment (22  1 C) under a 12:12 light/dark cycle (lightet al. 2002 ± °
from 6:00 AM to 6:00 PM), with access to familiar food (Irradiated Global 18  Protein Diet, Harlan Teklad) and water. Allad libitum %
animals used in this study arose from the same colony (BALBc/129 Sv mixed background). Experiments were performed in accordance
with French and European Community guidelines for the care and use of laboratory animals. All efforts were made to minimize the
number of animals and their suffering (86/609/EEC-Council Directive of November, 24 1986).th 
Drugs and long-term treatments
Drugs used for long-term treatments in this study were either (i) risperidone purchased from Janssen-Cilag Ltd (Risperdal , Beerse,®
Belgium), dissolved in drinking water or (ii) clozapine provided by Tocris Bioscience (Bristol, United Kingdom), resuspended with a few
drops of HCl before its volume was completed with NaCl (NaCl 0,9  sterile, Physiologica) and injected daily intra-peritoneally. We%
carefully estimated water consumption of WT and STOP-null mice in the presence or in the absence of risperidone and found no
differences between genotypes or treatments (average value for all groups: 15  of the body weight/day). Risperidone concentrations in the%
drinking water were calculated to obtain the desired delivered doses (0.1mg/kg/day and 0.3 mg/kg/day).
When mice reached 3 months, they were submitted to a long-term treatment with either antipsychotic drug or vehicle during 4 weeks.
The treatment was then pursued during a 3 to 4-weeks behavioral testing period.
Behavioral tests
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Drug-free and long-term APs-treated animals (4- to 5-month-old, 25 to 30 g) were investigated during the light phase, in a random
order for comparison between genotypes and treatments. Experimenter was blind to genotype during testing. In all experiments, animals
were allowed to habituate to the testing room 1 h before the test. The usual sequence of tests was as follows: Y-maze test, social
investigation test, marble burying test, forced swim test and electrophysiological recordings (see below). All the devices used for testing
were extensively washed with water between two animals to avoid olfactive cues. The luminosity of the testing room was controlled and
fixed around 30 35 Lux.–
Y-maze Test
Spontaneous alternation behavior and exploratory activity were recorded in a Y-maze. The apparatus was made of three equal arms
(dimensions: 20 cm long, 8 cm wide, 15 cm high) made of white polyvinyl chloride. The starting arm and the two arms forming the Y
were radiating at an angle of 120  from each other. Each mouse was placed in the starting arm of the maze and its position recorded during°
a 5-min session of free roaming by a video tracking system placed above the maze (Smart , Panlab, Harvard Apparatus). The total ®
distance traveled across the maze was automatically recorded. The sequence and number of arm entries were manually counted from
videotrack recordings. It was considered that a mouse had entered an arm when all four paws were positioned in the arm runway. A
spontaneous alternation was defined as entries into all three arms on 3 consecutive choices. The alternation score ( ) for each mouse was%
defined as the ratio of the actual number of alternations to the total possible number of alternations over the testing period:  Alternation % =
100   (Number of alternations)/(Total arm entries-2) . Mice that completed less than eight arm entries within 5 min were excluded from× [ ]
further analysis ( ).Sakaguchi et al. 2006 
Social investigation test
The social behavior of STOP and WT mice was assessed towards an encaged WT NMRI male mouse (Janvier, France) used as
intruder. Without any former isolation, a tested mouse was placed in an open field (50 cm long, 50 cm wide, 20 cm high) containing a wire
mesh cylinder in a corner (diameter: 12 cm; height: 14 cm; mesh dimensions: 6 mm) and covered with a lid. After habituation of the
animal to its new environment for 5 min, the intruder was introduced in the cylinder and the number of contacts and contact duration were
measured during a 10-min session. A contact was defined as a direct sniffing and full use of vibrissae performed by the tested animal
towards the intruder.
Marble burying test
The procedure for marble burying was adapted with minor modifications from that described by ( ). Briefly, miceMillan et al. 2001 
were individually placed in transparent polysulfone cages (dimensions: 36 X 21 X 14 cm) containing a 4-cm layer of sawdust and 12 glass
marbles (diameter: 1.6 cm) evenly spaced over the cage (3 rows of 4 marbles). In order to prevent escape, the cage was covered with a
filtering lid. Thirty minutes later, the animals were removed from the cages and the number of marbles buried more than two-thirds in the
sawdust was scored.
Forced Swim Test
Studies were carried out on mice according to the slightly modified method of Porsolt and co-workers ( ). AnimalsPorsolt et al. 1977 
were placed individually into polypropylene beakers (height 20 cm, diameter 16 cm) containing 2.5 liters of water (12-cm high)
maintained at 20 22 C. The animals were left in the beaker for 6 min. After the first 2 min, total duration of immobility was measured by a– °
well-trained experimenter during a 4-min session. Visually, the mouse was judged to be immobile when it remained floating passively,
performing slow motion to keep its head above the water.
Electrophysiological recordings
For preparation of hippocampal slices, adult mice (5 month-old) were deeply anesthetized with ketamine. Brain slices (300 m thick)μ
were cut in a cold cutting  artificial cerebrospinal fluid (ACSF) of the following composition (in mM): NaCl (0), KCl (2.5), MgCl2 (7),“ ”
CaCl2 (0.5), D-Glucose (10), NaHCO3 (26), NaH2PO4 (1.25), Sucrose (230). Slices were then submerged in a waiting chamber in “
recording  ACSF equilibrated with 95  O2 and 5  CO2 of the following composition (in mM): NaCl (124), KCl (5), MgCl2 (2), CaCl2” % %
(2), D-Glucose (11), NaHCO3 (26), NaH2PO4 (1.25) and maintained at room temperature for at least one hour before recording.
Recordings were done using microelectrode array (MEA) technology allowing stimulation and recording of bioelectrical activity from
different areas of the slice. For recordings, slices were placed within the recording chamber of a MEA probe (64 64 planar×
microelectrodes for Med64 apparatus, Panasonic) with perfusion of recording  ACSF equilibrated with 95  O2 and 5  CO2 and“ ” % %
maintained at 29 30 C. Stimulation was applied on Schaeffer collaterals every 30 sec during baseline (10 min) and after tetanus (TB, 100– °
Hz, 1 sec) (60 min) and recordings of field EPSPs were made within Ammon s Horn 1. Normalized field EPSP amplitudes were calculated’
and only slices showing i) less than 10  variation during the first 10 min of recording before tetanus, ii) more than 10  variation directly% %
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following the tetanus and iii) less than 20  variation during the post-tetanus recording were kept for further analysis. Electrophysiological%
data were plotted as a function of time and comparisons were performed between pooled data recorded 30 to 40 minutes after occurrence
of the LTP protocol as previously described ( ).Andrieux et al. 2002 
Statistical analysis
All statistical analyses were performed using Prism 4.0 (GraphPad Software, La Jolla, CA) and data were represented as boxed
medians with 25th and 75th percentiles and error bars corresponding to the lowest and the highest data points. For all tests, results were
compared between WT and KO placebo groups first, using unpaired non-parametric Mann- Whitney tests. To assay APs effect,
comparisons were then separately performed for each genotype (WT: placebo, dose 1, dose 2 and KO: placebo, dose 1, dose2) using
non-parametric Kruskals-Wallis ANOVA tests followed by Dunns  post-hoc comparisons.’
Results
We monitored the effect of long-term treatments with atypical antipsychotics (APs) on STOP-null mice, using several behavioral
tasks. Mice of WT and STOP KO genotypes were submitted to a chronic treatment with risperidone, clozapine or vehicle during 4 weeks.
The treatment was then pursued during the 3 to 4-weeks behavioral testing period. Since risperidone was administrated in the drinking
water while clozapine was injected daily, placebo groups can not be directly compared and each treated group will be compared to the
corresponding placebo.
Social investigation test
Social investigation has been addressed by measuring the number of contacts and contact duration between an immobilized intruder
mouse (male NMRI) and a freely-moving mouse to be tested. Results are presented in . In drug free animals, as compared to WT,Fig. 1 
STOP-null mice exhibited a reduction of social investigation affecting both the number of contacts with the intruder 9.5 vs 20 for KO and[
WT placebo mice in risperidone groups (  0.006) and 4.5 vs 12.5 for KO and WT placebo mice in clozapine groups (  0.200)  and thep = p = ]
time spent in social investigation 9 vs 29 sec for KO and WT placebo mice in risperidone groups (  0.006) and 6.5 vs 30.5 sec for KO[ p =
and WT placebo mice in clozapine groups (  0.029) .p = ]
We then assessed social behavior of STOP-null mice after long-term administration of risperidone or clozapine.
In WT mice, risperidone treatment did not affect the number of contacts 20 (placebo), 20 (0.1mg/kg/day), 19.5 (0.3mg/kg/day); [ p =
0.890  or time spent in investigation 29 sec (placebo), 33 sec (0.1mg/kg/day), 33 sec (0.3mg/kg/day);  0.316 . STOP-null mice groups] [ p = ]
displayed significant differences in number of contacts 9.5 (placebo), 17 (0.1mg/kg/day), 23 (0.3mg/kg/day);  0.012  and time spent in[ p = ]
investigation 9 sec (placebo), 18 sec (0.1mg/kg/day), 22 (0.3 mg/kg/day);  0.005 . In both sets of observations, post-hoc analyses show[ p = ]
significant improvement of STOP-null mice treated with risperidone 0.3 mg/kg/day as compared to placebo ( < 0.01).p 
In WT mice, clozapine treatment did not affect the number of contacts 12.5 (placebo), 12 (1mg/kg/day), 10.5 (3mg/kg/day);  0.924[ p =
 or time spent in investigation 30.5 sec (placebo), 28 sec (1mg/kg/day), 32 sec (3mg/kg/day);  0.909 . STOP-null mice groups also] [ p = ]
displayed significant differences in number of contacts 4.5 (placebo), 7 (1mg/kg/day), 8 (3 mg/kg/day);  0.030  and time spent in[ p = ]
investigation 6.5 sec (placebo), 14 sec (1mg/kg/day), 25.5 sec (3 mg/kg/day);  0.015 . Again, post-hoc analyses show significant[ p = ]
improvement of STOP-null mice treated with clozapine 3 mg/kg/day as compared to placebo ( < 0.05).p 
Altogether these results indicate that long term treatment with APs risperidone or clozapine alleviate social behavioral impairment in
STOP-null mice.
Marble burying test
In rodents, digging of bedding and burying of objects considered as dangerous for the animal are natural tendencies that do not depend
on the nature of their environment (laboratory or nature). The marble burying assay has been predominantly used for the screening of
anxiolytic compounds ( ; ).Nicolas et al. 2006 Young et al. 2006 
In the marble burying test, each mouse was introduced in a cage containing 12 marbles and left free to roam for 30 minutes; the
number of buried marbles was then counted. Results are presented in .Fig. 2 
In drug free animals, as compared to WT, STOP-null mice buried less marbles 0 vs 9 for KO and WT placebo mice in risperidone[
groups ( 0.042) and 0 vs 7 for KO and WT placebo mice in clozapine groups (  0.017) .p = p = ]
The ability to bury marbles was then investigated in risperidone or clozapine long-term-treated animals.
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In WT mice, risperidone treatment did not affect the number of buried marbles 9 (placebo), 9 (0.1mg/kg/day), 9 (0.3mg/kg/day); [ p =
0.887  while STOP-null mice groups showed nearly significant increases in number of buried marbles 0 (placebo), 6.5 (0.1mg/kg/day), 6] [
(0.3mg/kg/day);  0.084 .p = ]
In WT mice, clozapine treatment did not affect the number of buried marbles 7 (placebo), 7 (0.1mg/kg/day), 8 (0.3mg/kg/day); [ p =
0.920  while STOP-null mice groups showed non-significant increases in number of buried marbles 0 (placebo), 0 (0.1mg/kg/day), 5] [
(0.3mg/kg/day);  0.329 .p = ]
These results indicate that although both long-term treatments increased STOP-null mice ability to bury marbles, none did so to a
significant level.
Forced swim test
Resignation/despair was assessed in a forced swim test. Mice were placed in a glass beaker containing water for 6 minutes and
immobility was measured during the last 4 minutes. Results are presented in .Fig. 3 
In drug free animals, as compared to WT, STOP-null mice stayed immobile longer 127.5 vs 73.5 sec for KO and WT placebo mice in[
risperidone groups (p 0.114) and 95.5 vs 49.5 sec for KO and WT placebo mice in clozapine groups (p  0.019) .= = ]
We then assessed resignation of STOP-null mice after long-term administration of risperidone or clozapine.
Total immobility of WT animals was not modified by risperidone treatment 73.5 sec (placebo), 73 sec (0.1mg/kg/day), 68.5 sec[
(0.3mg/kg/day);  0.362 . STOP-null mice groups displayed significant differences in the time of immobility 127.5 sec (placebo), 93.5p = ] [
sec (0.1mg/kg/day) and 70.5 sec (0.3mg/kg/day);  0.005 . Post-hoc analysis showed significant improvement of STOP-null mice treatedp = ]
with risperidone 0.3 mg/kg/day as compared to placebo (p < 0.01).
Total immobility of WT animals was not modified by clozapine treatment 49.5 sec (placebo), 68 sec (1mg/kg/day), 60 sec[
(3mg/kg/day);  0.551 . STOP-null mice groups displayed significant differences in the time of immobility 95.5 sec (placebo), 88  7.19p = ] [ ±
sec (0.1mg/kg/day), 52 sec (0.3mg/kg/day);  0.028 . Post-hoc analyzes showed significant improvement of STOP-null mice treated withp = ]
risperidone 0.3 mg/kg/day as compared to placebo (p < 0.05).
Altogether, these results indicate increased resignation in STOP-null mice which is ameliorated by AP long-term treatments.
Y-maze test
Spatial working memory was assessed by testing the spontaneous alternation performance of mice in a Y-maze during a 5-min session
of free roaming. Exploratory activity was estimated by the total distance traveled across the maze. The alternation score for each mouse
was defined as the ratio of the actual number of alternations to the total possible number of alternations. Results are presented in .Fig. 4 
In drug-free animals, as compared to WT, STOP-null mice displayed the same exploratory activity measured from the total distance
traveled (data not shown) but displayed significantly less spontaneous alternation performance 52.5 vs 63.6  for KO and WT placebo[ %
mice in risperidone groups ( 0.010) .p = ]
Risperidone treated or untreated STOP-null mice only showed slight differences in spontaneous alternation 52.5  (placebo), 64.6 [ % %
(0.1mg/kg/day), 60.7  (0.3mg/kg/day); 0.219 . These results indicate impairment of working memory in STOP-null mice and a limited% p = ]
beneficial effect of risperidone long-term treatment.
Hippocampal Long-Term Potentiation
STOP-null mice have been shown to display severe defects in long-term synaptic plasticity with highly reduced Long-Term
Potentiation (LTP) in the CA1 region of the hippocampus ( ). Here, we studied the effect of chronic treatment withAndrieux et al. 2002 
risperidone or clozapine on LTP. In the clozapine group (daily injection of either clozapine or vehicle), STOP-null mice exhibited reduced
LTP as compared to wild type 127.9  vs 165.5  (normalized field EPSP amplitudes measured between 30 and 40 minutes post-tetanus)[ % %
for KO and WT placebo mice ( 0.006)  ( ). Synaptic potentiation was obviously improved by clozapine treatments at early timep = ] Fig. 5b 
points and persisted for at least 1 hour ( ). Quantitative analysis showed that after clozapine treatment, STOP-null mice groupsFig. 5a 
exhibited significant differences in LTP values measured between 30 and 40 minutes post-tetanus 127.9  (placebo), 136.3[ % %
(3mg/kg/day), 171.1  (10 mg/kg/day); normalized field EPSP amplitudes, 0.027  ( ). Post-hoc analysis showed significant% p = ] Fig. 5b 
improvement of STOP-null mice LTP with clozapine 10 mg/kg/day as compared to placebo (p < 0.05). Risperidone treatment did not
alleviate LTP defects of STOP-null mice (data not shown).
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Discussion
The goal of the present work was to assay the sensitivity to a long-term atypical AP treatment, namely clozapine and risperidone, on
behavioural and synaptic impairments exhibited by STOP-null mice. The present study extended the behavioural phenotype of STOP-null
mice revealing that STOP (MAP6) gene deletion in mice leads to multiple behavioural abnormalities relevant to negative symptoms and
cognitive impairments of schizophrenia.
In schizophrenia, negative symptoms are close to most of depression symptoms ( ). Social interactions measured inBarnes et al. 1989 
rodents are directly comparable to social interaction measured in humans. It has been previously described that STOP-null mice show
severe social withdrawal both in aggressive and non-aggressive components (Andrieux et al.2002; ). In this study, usingB gou et al. 2008 é
a new paradigm, we found a strong decrease in number of contacts and time spent sniffing in STOP-null mice, indicating a marked social
deficit. Interestingly, both clozapine and risperidone long-term treatments strongly improved social interactions in STOP-null mice
whereas typical AP long-term treatments have been shown to be less active ( ).B gou et al. 2008 é
The behavioural despair of the animal, placed in an unusual and inescapable environment ( ; ) andPorsolt et al. 1978 Porsolt et al. 1977 
revealed through increased immobility in the forced swim test, could be notably due to a loss of motivation ( ; Noda et al. 1997 Noda et al.
) and so relevant to the negative symptomatology in animal models of schizophrenia. In this study, STOP-null mice spent more time1995 
floating with minimum movements than WT mice. This altered behaviour of STOP-null mice may potentially be the consequence of an
intrinsic lack of motivation as already suspected in a previous study ( ). Comparable deficits have been observed inB gou et al. 2008 é
transgenic mice expressing dominant negative copies of DISC1, another genetic model for schizophrenia ( ). ChronicHikida et al. 2007 
treatments with either clozapine or risperidone alleviate behavioural despair in STOP-null mice, potentially by improving their
motivational ability.
Whereas marble burying is more closely related to impulsive behaviour than anxious states, this test has been predominantly used as a
screening model of detection of new anxiolytic compounds ( ; ). STOP-null mice bury a substantiallyNicolas et al. 2006 Young et al. 2006 
lower number of marbles than WT mice. Such behaviour could rely on low anxious state or low motivation for physical environment. Low
anxious state is also observed in the elevated plus maze test, as STOP-null mice spent more time in the open arms than WT animals (D. D.
unpublished observations) and low motivation for physical environment has already been suggested from STOP-null mice unable to
perform object recognition tests ( ). In any case, long-term treatment with either clozapine or risperidone increased theAndrieux et al. 2002 
number of buried marbles, but never to significant levels. Better suited tests for anxiety versus motivation should be used in the future.
It has been previously demonstrated that STOP-null mice present cognitive deficits related to the episodic ( ),Andrieux et al. 2002 
social, spatial and working memories ( ). Here, we actually show that chronic treatment with risperidone does not restoreB gou et al. 2008 é
impairment in spatial short-term working memory of STOP-null mice in the spontaneous alternation task.
Altogether these results clearly indicate that STOP-null mice exhibit strong deficits related to negative symptoms and cognitive
impairments of schizophrenia. Atypical APs significantly improve deficits related to negative symptoms in STOP-null mice while typical
APs only slightly alleviate them ( ). In parallel, atypical APs display a slight benefit effect on the cognitive impairmentsB gou et al. 2008 é
in STOP-null mice, known to be resistant to typical treatment with haloperidol ( ).B gou et al. 2008 é
Typical versus atypical APs sensitivity of STOP-null mice are in accordance with clinical data showing that clozapine and risperidone
have a trend to a positive action on negative impairments equivalent or superior to the typical APs, particularly versus haloperidol (Leucht
; ). The poor effect of atypical APs treatment on cognitive functions in STOP-null mice is compatible withet al. 2009 Volavka et al. 2002 
the effects of atypical APs in humans. Typical APs have been shown to be deleterious on cognitive abilities in humans whereas atypical
APs do not induce these defects. In total, we detected the same pharmacological reactivity of typical/atypical APs on STOP-null mice
behaviour. The beneficial effect of atypical APs on negative and cognitive impairments over typical drugs is thought to be linked to their
pharmacological profile, atypical APs exhibiting higher affinity for 5-HT-2 receptors than typical APs ( ).Duncan et al. 1999 
A growing body of evidence involves glutamatergic transmission in the aetiology of schizophrenia and drugs directly targeting
glutamatergic receptors have been shown to exhibit antipsychotic properties ( ). Accordingly, STOP-null mice displayPatil et al. 2007 
abnormal glutamatergic neurotransmission revealed by impaired long-term potentiation ( ). Some beneficial effects ofAndrieux et al. 2002 
clozapine are thought to occur through glutamatergic transmission ( ; ) and interestingly, long-termCoyle and Tsai 2004 Frankle et al. 2003 
treatment of STOP-null mice with clozapine restored LTP whereas risperidone did not. These results indicate that LTP measurements in
STOP-null mice may discriminate between APs with or without glutamatergic profiles.
A translational preclinical model of human psychiatric disorder is all the more relevant that it respects construct, face and predictive
validity ( ; ). As outlined in the introduction STOP-null mouse model fulfils theEllenbroek and Cools 1990 Miczek and de Wit 2008 
construct and face validity: it is constructed from the neurodevelopmental hypothesis of schizophrenia, with synaptic impairment. Indeed,
an association between single nucleotide polymorphism markers of the MAP6 gene and schizophrenia has been found (Shimizu et al. 2006
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) as well as a deregulation of STOP expression inprefrontal cortex of schizophrenic patients ( ). STOP-nullMartins-de-Souza et al. 2009 
mice have been shown to display behavioral abnormalities thought to simulate aspects of positive symptoms classically observed in
schizophrenic patients. The present data, added to all previous ones, give a comprehensive phenotype of STOP null mice according to the
behavioral defects related to the core symptoms of schizophrenia, namely negative symptoms and cognitive deficits, which are known to
be resistant to current treatments. The pharmacological results of the present study referring to the possibility to mimic the benefit effects
of APs in humans are relevant for the predictive validity of STOP-null mice. However, knowing that current atypical AP treatment in
humans displayed limited effects, the predictive validity of STOP null mice need to be further supported by studies showing behavioral
alterations resistant to APs. Altogether, we suggest that STOP null mice could be a very useful tool to develop AP drugs by monitoring
pharmacological effects both at the behavioural and biological levels.
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Fig. 1
Social investigation test. Number (a and b) and total duration (c and d) of contacts with the intruder in placebo and long-term risperidone (a
and c) or clozapine (b and d) -treated WT and STOP-null mice. STOP-null mice treated with placebo present a social withdrawal when
compared with their WT littermates , , : >0.05, <0.05, <0.01, respectively, KO vs WT placebo . Chronic treatment with risperidone[ns * ** p p p ]
or clozapine significantly improved social behaviour in STOP-null mice , : <0.05, <0.01, respectively, between KO groups, with [# ## p p A 
different from , <0.01for risperidone (a and c) and <0.05 for clozapine (b and d) long-term treatments . Note that clozapine andC p p ]
risperidone are not administrated the same way (injection and drinking water, respectively) preventing direct comparisons between the two
groups
Fig. 2
Marble burying test. Number of buried marbles in placebo and long-term risperidone (a) or clozapine (b) -treated WT and STOP-null mice.
STOP-null mice treated with placebo bury fewer marbles when compared with their WT littermates : <0.05, KO vs WT placebo . Chronic[* p ]
treatment of STOP-null mice with risperidone or clozapine enhanced the number of buried marbles in a non significant  way[ns ]
Fig. 3
Forced swim test. Total time of immobility in placebo and long-term risperidone (a) or clozapine (b) -treated WT and STOP-null mice.
Immobility time was longer in STOP-null mice treated with placebo compared with their WT littermates , : >0.05, <0.05,[ns * p p 
respectively, KO vs WT placebo . Administration of a chronic treatment with either risperidone or clozapine produced a significant decrease]
in immobility time in STOP-null mice , : <0.05, <0.01, respectively, between KO groups, with different from , <0.01 for[# ## p p A C p 
risperidone (a) and <0.05 for clozapine (b) long-term treatmentsp ]
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Fig. 4
Spontaneous alternation task (Y-Maze) in placebo and long-term risperidone-treated WT and STOP-null mice. STOP-null mice treated with
placebo present an impairment of spatial working memory when compared to their WT littermates : <0.05, KO vs WT placebo . Chronic[* p ]
treatment with risperidone slightly improved STOP-null mice performance in the Y maze although not significantly [ns ]
Fig. 5
Electrophysiological recordings of LTP. (a) Normalized field EPSP amplitude recorded during 10 min before and 60 min after tetanus (100
Hz, 1 sec) for placebo (  10 slices), clozapine 3 mg/kg/day (  16 slices) and clozapine 10mg/kg/day (  6 slices) STOP null mice. (b)n = n = n =
Normalized field EPSP amplitudes between 30 and 40 min after tetanus. In wild type mice, LTP values were similar in all studied groups
(untreated, placebo and clozapine-treated) and the value for WT placebo group is shown for comparisons; STOP-null mice treated with
placebo present an impairment of LTP when compared to their WT littermates : <0.01, KO vs WT placebo . Only the dose of 10[** p ]
mg/kg/day of clozapine significantly improved LTP of chronically-treated mice : <0.05 between KO groups, with different from , [# p A C p 
<0.05]
